Literature DB >> 23162101

The metabolic profile in active acromegaly is gender-specific.

A Ciresi1, M C Amato, R Pivonello, E Nazzari, L F Grasso, F Minuto, D Ferone, A Colao, C Giordano.   

Abstract

CONTEXT: The sexual dimorphism of the somatotroph axis has been documented, but whether the acromegaly-related metabolic alterations are gender-dependent has never been investigated.
OBJECTIVE: The aim of the study was to evaluate the impact of gender on the metabolic parameters in acromegaly.
DESIGN: We conducted a retrospective, comparative, multicenter study. PATIENTS: The 307 newly diagnosed acromegalic patients included in the study were grouped by gender: 157 men (aged 48.01 ± 14.28 yr), and 150 women (aged 48.67 ± 14.95 yr; of which 77 were premenopausal and 73 postmenopausal). OUTCOME MEASUREMENTS: We measured each component of the metabolic syndrome (MS), hemoglobin A1c, the areas under the curve (AUCs) of glucose and insulin during 2-h oral glucose tolerance test, basal insulin resistance using the homeostasis model assessment of the insulin resistance index, stimulated insulin sensitivity using the insulin sensitivity index, early insulin-secretion rate using the insulinogenic index, β-cell function relative to insulin sensitivity using the oral disposition index and the visceral adiposity index (VAI) as the surrogate of visceral fat function.
RESULTS: Women showed a higher prevalence of MS (P < 0.001), higher fasting insulin levels (P < 0.001), AUC for insulin (P = 0.002), homeostasis model assessment of the insulin resistance index (P < 0.001), and VAI (P < 0.001) and a lower insulin sensitivity index (P = 0.002) than men, whereas no difference was found in fasting glucose, AUC for glucose, hemoglobin A1c, insulinogenic index, and oral disposition index. In women, fasting glucose and fasting insulin showed a significant trend toward increase (P < 0.001) and decrease (P = 0.004), respectively, from the first to the fourth quartiles of age, whereas VAI showed a trend toward increase in both groups (P < 0.001). A significantly higher prevalence of MS (P < 0.001), increased waist circumference (P < 0.001), low high-density lipoprotein cholesterol (P < 0.001), and overt diabetes mellitus (P < 0.001) was found in postmenopausal women compared with premenopausal women, as well as with men.
CONCLUSIONS: The majority of metabolic features in acromegaly are gender-specific. Active acromegaly in women is strongly associated with higher visceral adiposity dysfunction, insulin resistance, and the features of MS. We suggest more accurate metabolic management in acromegalic women, especially in the postmenopausal years.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23162101     DOI: 10.1210/jc.2012-2896

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  22 in total

1.  IGF-1 levels across the spectrum of normal to elevated in acromegaly: relationship to insulin sensitivity, markers of cardiovascular risk and body composition.

Authors:  Tirissa J Reid; Zhezhen Jin; Wei Shen; Carlos M Reyes-Vidal; Jean Carlos Fernandez; Jeffrey N Bruce; Jane Kostadinov; Kalmon D Post; Pamela U Freda
Journal:  Pituitary       Date:  2015-12       Impact factor: 4.107

2.  Impact of acromegaly treatment on cardiovascular complications.

Authors:  Adriana G Ioachimescu
Journal:  Endocrine       Date:  2017-02-03       Impact factor: 3.633

3.  Visceral adiposity index as an indicator of cardiometabolic risk in patients treated for craniopharyngioma.

Authors:  Francesco Ferraù; Federica Spagnolo; Oana Ruxandra Cotta; Laura Cannavò; Angela Alibrandi; Giuseppina Tiziana Russo; Tommaso Aversa; Francesco Trimarchi; Salvatore Cannavò
Journal:  Endocrine       Date:  2016-12-16       Impact factor: 3.633

4.  The tendency of reduced periodontal destruction in acromegalic patients showing similar inflammatory status with periodontitis patients.

Authors:  Yesim Ozdemir; H Gencay Keceli; Nafiye Helvaci; Tomris Erbas; Rahime M Nohutcu
Journal:  Endocrine       Date:  2019-09-02       Impact factor: 3.633

5.  Alteration of the growth hormone axis, visceral fat dysfunction, and early cardiometabolic risk in adults: the role of the visceral adiposity index.

Authors:  Carolina Di Somma; Alessandro Ciresi; Marco C Amato; Silvia Savastano; Maria Cristina Savanelli; Elisabetta Scarano; Annamaria Colao; Carla Giordano
Journal:  Endocrine       Date:  2014-11-09       Impact factor: 3.633

Review 6.  Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities.

Authors:  Rosario Pivonello; Renata S Auriemma; Ludovica F S Grasso; Claudia Pivonello; Chiara Simeoli; Roberta Patalano; Mariano Galdiero; Annamaria Colao
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

7.  A multicenter, observational study of lanreotide depot/autogel (LAN) in patients with acromegaly in the United States: 2-year experience from the SODA registry.

Authors:  Roberto Salvatori; Murray B Gordon; Whitney W Woodmansee; Adriana G Ioachimescu; Don W Carver; Beloo Mirakhur; David Cox; Mark E Molitch
Journal:  Pituitary       Date:  2017-12       Impact factor: 4.107

8.  The visceral adiposity index is associated with insulin sensitivity and IGF-I levels in adults with growth hormone deficiency.

Authors:  Alessandro Ciresi; Stefano Radellini; Valentina Guarnotta; Carla Giordano
Journal:  Endocrine       Date:  2016-08-13       Impact factor: 3.633

9.  Diagnosis and management of acromegaly: the patient's perspective.

Authors:  Ilonka Kreitschmann-Andermahr; Sonja Siegel; Bernadette Kleist; Johannes Kohlmann; Daniel Starz; Rolf Buslei; Maria Koltowska-Häggström; Christian J Strasburger; Michael Buchfelder
Journal:  Pituitary       Date:  2016-06       Impact factor: 4.107

10.  Gender differences and temporal trends over two decades in acromegaly: a single center study in 112 patients.

Authors:  Adriana G Ioachimescu; Talin Handa; Neevi Goswami; Adlai L Pappy; Emir Veledar; Nelson M Oyesiku
Journal:  Endocrine       Date:  2019-11-01       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.